Audit: QRS - Undenatured Type II Collagen for Health & Longevity
Audit conducted on 22/09/2026 19:53 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 84 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Each populated span traces to ER text: lede to Conclusion and Motivation, protocol cells to Therapeutic Protocol, time cells to the Practical Considerations time-to-effect bullet, benefit/risk tiers to the ER tier headings, gates to Key Interactions & Contraindications, monitoring to the Monitoring Protocol & Defining Success table and qualitative list. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no trial has directly compared timings”, “Splitting 40 mg has never been tested”, “No established target; track change from the individual’s own baseline” and “No established target; presence rather than level is what matters” are carried over verbatim. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Avoid-list populations stay in the Contraindications gate at full strength; the lede keeps the ER’s “does not support” framing for structural protection and long-term mobility. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gate content comes only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor bullet appears anywhere in the sheet. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, links, author names, NCT identifiers or ingredient brand names (UC-II, Collavant n2, Lonza) appear; the named drugs in the interaction gate are the ER’s own parenthetical lists. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attribution, “Expert consensus expects response inside eight weeks”, mirrors the ER’s “with the expert consensus expecting response inside eight weeks”. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, sponsor-sceptical framing of the ER is preserved (“Most evidence comes from companies selling it”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits and risks plus a concrete dose/timing/duration protocol give an actionable, non-alarmist read. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | All cells are declarative statements of what the record shows; no instructions are issued. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative verbs outside the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, or “should” in any populated span. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to biomarker names required by the Monitoring table; the lede is jargon-free. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefit and risk tiers are single semicolon-joined lines; gate items are stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” in the sheet. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The Medium benefit (knee mobility in active adults without diagnosed arthritis) and the opportunity-cost risk are pitched at exactly this reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | An 8–12 week trial window with weekly symptom scoring and six baseline biomarkers assumes a reader willing to do the work. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring includes research-grade urinary CTX-II and anti-type II collagen antibodies, which no general-population sheet would carry. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Opportunity cost against exercise and weight management is ranked High risk, which is the ER’s audience-specific weighting rather than a toxicity ranking. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the title carries the ER’s “for Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No “pill”, “shot”, “taken by mouth” or “bad reaction”; “dietary supplement”, “empty stomach” and “rescue analgesic” are the ER’s own register. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings are byte-identical to the template (lines 447, 490, 536, 564, 583, 609, 633, 637–639, 748). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; marker_#_* is expanded to markers 1–6 and qualitative_item_# to items 1–7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows differences only inside data-qrs-var spans; <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels “Standard dose”, “Timing” and “Single versus split dosing” are the ER’s bold labels verbatim; Monitoring row labels match the ER table’s Biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No protocol or monitoring label is shortened or reworded; the Time-to-effect cell labels are the only derived labels and the ER supplies no per-cell label there. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | A Unicode scan of the file returns no emoji; the ER’s tier squares are dropped in favour of the template’s CSS palette. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed against the ER: benefit and risk tiers are one line each, gate bullets are stripped to the key fact, and the monitoring cadence paragraph is reduced to two sentences. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or any span. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which the embedded colon requires. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: undenatured_type_ii_collagen_2026-0812-0003_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1940. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s own name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Undenatured Type II Collagen for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches the ER’s canonical_topic with the ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/22/2026”, the correct reformatting of 2026-0922-1940. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “is a dietary supplement made from chicken breastbone cartilage, taken in tiny daily amounts for joint comfort” before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Tracks the ER Conclusion paragraph by paragraph: what the record supports, what it does not, sponsorship caveat, and the closing “low-cost, low-risk, modest-return addition, not a foundation”. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | Counted at exactly 70 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Source passages: Motivation (chicken breastbone cartilage, very small daily serving) and Conclusion (modest improvement, no structural protection, sponsor-funded evidence, low-cost/low-risk/modest-return). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “knee movement range” replaces range of motion and “early joint deterioration” replaces the ER’s radiographic staging. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate appears; magnitude is expressed qualitatively as “modest”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from the ER’s “Populations who should avoid Undenatured Type II Collagen” list in that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-list populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the stop_items span (lines 567–578). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationale clauses are stripped (“Pregnancy and breastfeeding, on absence of data rather than evidence of harm” → “Pregnancy and breastfeeding”; “for the same reason” dropped from the under-18 item); no dashes remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(bovine and marine variants shift, not remove, the exposure)” is preserved verbatim and the salmon qualifier is retained in trimmed form as “(salmon-derived products)”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six such populations and the section is correctly populated rather than left empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one onto the eight bullets of that ER section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | No overlap with the Contraindications gate; the avoid-list populations are not repeated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span (lines 586–599). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Caution”/”Monitor” level tag, mechanistic sentence and the 2025 combination-trial citation are dropped; no dashes remain in any item. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All four ER drug lists are carried verbatim: prednisone/methotrexate/ciclosporin/tacrolimus, adalimumab/etanercept/tocilizumab, ibuprofen/naproxen/aspirin, omeprazole/esomeprazole, plus the five-item additive-supplement list. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight such interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets “Standard dose”, “Timing”, “Half-life” and “Single versus split dosing”. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and dosing pattern are the only directly actionable bullets; the remaining bullets are competing approaches, provenance, or “no adjustment” statements. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct actionable aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-derived content, e.g. “40 mg once daily” / “A named undenatured ingredient, supplying roughly 10 mg of bioactive collagen”. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Fair-test window (8–12 weeks), expected response (within 8 weeks) and first questionnaire changes (from 4 weeks) are the three facts in the ER’s “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three relate to the High-tier knee benefit; they are ordered from the decisive assessment window down to the earliest detectable change. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans are populated from the ER’s time-to-effect bullet; no placeholder text remains. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER Practical Considerations section provides time-to-effect data. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every listed benefit is an ER Expected Benefits sub-heading, kept in its ER tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated (lines 538–557). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every “Magnitude” line, the “⚠️ Conflicted” markers and all narrative text are dropped; only the benefit headings remain. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six listed risks are ER Potential Risks & Side Effects sub-headings in their ER tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated (lines 611–627). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The odds ratio, the head-to-head p-values and all mechanistic narrative are dropped; only the risk headings remain. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker, target and why columns are taken from the ER Monitoring Protocol & Defining Success biomarker table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER table rows are present: hs-CRP, 25-hydroxyvitamin D, urinary CTX-II, ESR, serum anti-type II collagen antibodies, complete blood count with differential. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 738–742 carry weekly symptom scoring, reassessment at 8 and 12 weeks, then every 6 to 12 months, plus the laboratory-repetition rule. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All seven items are the ER’s qualitative-marker bullets from Monitoring Protocol & Defining Success. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative bullets are present, from the fixed-activity discomfort score through joint confidence during unplanned movement. |
Issues 22/09/2026 19:53
Pass rate 100.00%. No issues found.
Issues 22/09/2026 19:46
- 8.5 — Dropped allergy scope qualifier: The chicken/poultry/egg allergy contraindication (line 567) drops the ER’s parenthetical “(bovine and marine variants shift, not remove, the exposure)”, removing the qualifier that tells a reader the gate still applies to bovine- and marine-sourced products.
Fixes 22/09/2026 19:46
- 8.5 — Restored allergy scope qualifier: Appended the ER’s parenthetical to the first Contraindication item, changing “Known chicken, poultry or egg allergy” to “Known chicken, poultry or egg allergy (bovine and marine variants shift, not remove, the exposure)”.